{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:33:24Z","timestamp":1753180404393},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Biological systems are robust and complex to maintain stable phenotypes under various conditions. In these systems, drugs reported the limited efficacy and unexpected side-effects. To remedy this situation, many pharmaceutical laboratories have begun to research combination drugs and some of them have shown successful clinical results. Complementary action of multiple compounds could increase efficacy as well as reduce side-effects through pharmacological interactions. However, experimental approach requires vast cost of preclinical experiments and tests as the number of possible combinations of compound dosages increases exponentially. Computer model-based experiments have been emerging as one of the most promising solutions to cope with such complexity. Though there have been many efforts to model specific molecular pathways using qualitative and quantitative formalisms, they suffer from unexpected results caused by distant interactions beyond their localized models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In this work, we propose a rule-based multi-scale modelling platform. We have tested this platform with Type 2 diabetes (T2D) model, which involves the malfunction of numerous organs such as pancreas, circulation system, liver, and adipocyte. We have extracted T2D-related 190 rules by manual curation from literature, pathway databases and converting from different types of existing models. We have simulated twenty-two T2D drugs. The results of our simulation show drug effect pathways of T2D drugs and whether combination drugs have efficacy or not and how combination drugs work on the multi-scale model.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We believe that our simulation would help to understand drug mechanism for the drug development and provide a new way to effectively apply existing drugs for new target. It also would give insight for identifying effective combination drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1472-6947-13-s1-s4","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T10:19:18Z","timestamp":1365157158000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Rule-based multi-scale simulation for drug effect pathway analysis"],"prefix":"10.1186","volume":"13","author":[{"given":"Woochang","family":"Hwang","sequence":"first","affiliation":[]},{"given":"Yongdeuk","family":"Hwang","sequence":"additional","affiliation":[]},{"given":"Sunjae","family":"Lee","sequence":"additional","affiliation":[]},{"given":"Doheon","family":"Lee","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2013,4,5]]},"reference":[{"key":"651_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-pharmtox-010611-134520","volume":"52","author":"S Zhao","year":"2012","unstructured":"Zhao S, Iyengar R: Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annual review of pharmacology and toxicology. 2012, 52: 505-521. 10.1146\/annurev-pharmtox-010611-134520.","journal-title":"Annual review of pharmacology and toxicology"},{"issue":"10","key":"651_CR2","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/nbt1017","volume":"22","author":"EC Butcher","year":"2004","unstructured":"Butcher EC, Berg EL, Kunkel EJ: Systems biology in drug discovery. Nature biotechnology. 2004, 22 (10): 1253-1259. 10.1038\/nbt1017.","journal-title":"Nature biotechnology"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010611-134630","volume":"52","author":"L Xie","year":"2012","unstructured":"Xie L, Kinnings SL, Bourne PE: Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annual review of pharmacology and toxicology. 2012, 52: 361-379. 10.1146\/annurev-pharmtox-010611-134630.","journal-title":"Annual review of pharmacology and toxicology"},{"issue":"5","key":"651_CR4","doi-asserted-by":"publisher","first-page":"e1000387","DOI":"10.1371\/journal.pcbi.1000387","volume":"5","author":"L Xie","year":"2009","unstructured":"Xie L, Li J, Bourne PE: Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS computational biology. 2009, 5 (5): e1000387-10.1371\/journal.pcbi.1000387.","journal-title":"PLoS computational biology"},{"issue":"2","key":"651_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.mvr.2008.08.003","volume":"77","author":"L Lu","year":"2009","unstructured":"Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, Man HW, Chen RS, Muller GW, Hughes CC, Stirling DI, et al: The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvascular research. 2009, 77 (2): 78-86. 10.1016\/j.mvr.2008.08.003.","journal-title":"Microvascular research"},{"issue":"10","key":"651_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/nbt1007-1110","volume":"25","author":"AL Hopkins","year":"2007","unstructured":"Hopkins AL: Network pharmacology. Nature biotechnology. 2007, 25 (10): 1110-1111. 10.1038\/nbt1007-1110.","journal-title":"Nature biotechnology"},{"issue":"2","key":"651_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, et al: Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. The New England journal of medicine. 2012, 366 (2): 109-119. 10.1056\/NEJMoa1113216.","journal-title":"The New England journal of medicine"},{"issue":"10","key":"651_CR8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH: The NCI60 human tumour cell line anticancer drug screen. Nature reviews Cancer. 2006, 6 (10): 813-823. 10.1038\/nrc1951.","journal-title":"Nature reviews Cancer"},{"key":"651_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1752-0509-3-81","volume":"3","author":"A Vazquez","year":"2009","unstructured":"Vazquez A: Optimal drug combinations and minimal hitting sets. BMC systems biology. 2009, 3: 81-10.1186\/1752-0509-3-81.","journal-title":"BMC systems biology"},{"key":"651_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1752-0509-5-109","volume":"5","author":"J Jack","year":"2011","unstructured":"Jack J, Wambaugh JF, Shah I: Simulating quantitative cellular responses using asynchronous threshold Boolean network ensembles. BMC systems biology. 2011, 5: 109-10.1186\/1752-0509-5-109.","journal-title":"BMC systems biology"},{"issue":"13","key":"651_CR11","doi-asserted-by":"publisher","first-page":"i310","DOI":"10.1093\/bioinformatics\/btr202","volume":"27","author":"G Jin","year":"2011","unstructured":"Jin G, Zhao H, Zhou X, Wong ST: An enhanced Petri-net model to predict synergistic effects of pairwise drug combinations from gene microarray data. Bioinformatics. 2011, 27 (13): i310-316. 10.1093\/bioinformatics\/btr202.","journal-title":"Bioinformatics"},{"key":"651_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/msb.2008.53","volume":"4","author":"S Nelander","year":"2008","unstructured":"Nelander S, Wang W, Nilsson B, She QB, Pratilas C, Rosen N, Gennemark P, Sander C: Models from experiments: combinatorial drug perturbations of cancer cells. Molecular systems biology. 2008, 4: 216-","journal-title":"Molecular systems biology"},{"issue":"24","key":"651_CR13","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1056\/NEJMra0906948","volume":"363","author":"MI McCarthy","year":"2010","unstructured":"McCarthy MI: Genomics, type 2 diabetes, and obesity. The New England journal of medicine. 2010, 363 (24): 2339-2350. 10.1056\/NEJMra0906948.","journal-title":"The New England journal of medicine"},{"key":"651_CR14","volume-title":"The Music of Life: Biology Beyond the Genome","author":"N D","year":"2006","unstructured":"D N: The Music of Life: Biology Beyond the Genome. 2006, Oxford University Press"},{"key":"651_CR15","first-page":"179","volume-title":"'Downward causation' in hierarchically organised biological systems","author":"C DT","year":"1974","unstructured":"DT C: 'Downward causation' in hierarchically organised biological systems. 1974, Macmillan Press, 1974: 179-186."},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-3-540-74407-8_3","volume-title":"Rule-Based Modelling of Cellular Signalling CONCUR 2007 - Concurrency Theory","author":"V Danos","year":"2007","unstructured":"Danos V, Feret J, Fontana W, Harmer R, Krivine J: Rule-Based Modelling of Cellular Signalling CONCUR 2007 - Concurrency Theory. Edited by: Caires L, Vasconcelos V. 2007, Springer Berlin\/Heidelberg, 4703: 17-41. 10.1007\/978-3-540-74407-8_3."},{"issue":"4","key":"651_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/cplx.20074","volume":"10","author":"JR Faeder","year":"2005","unstructured":"Faeder JR, Blinov ML, Goldstein B, Hlavacek WS: Rule-based modeling of biochemical networks. Complexity. 2005, 10 (4): 22-41. 10.1002\/cplx.20074.","journal-title":"Complexity"},{"key":"651_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1145\/2390068.2390083","volume-title":"Proceedings of the ACM Sixth International Workshop on Data and Text Mining in Biomedical Informatics","author":"W Hwang","year":"2012","unstructured":"Hwang W, Hwang Y, Lee S, Lee D: Rule-based whole body modeling for analyzing multi-compound effects. Proceedings of the ACM Sixth International Workshop on Data and Text Mining in Biomedical Informatics. 2012, New York: ACM, 77-84. 10.1145\/2390068.2390083."},{"key":"651_CR19","volume-title":"Pharmacology","author":"R Finkel","year":"2009","unstructured":"Finkel R: Pharmacology. 2009"},{"issue":"7305","key":"651_CR20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","volume":"466","author":"JH Choi","year":"2010","unstructured":"Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, et al: Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature. 2010, 466 (7305): 451-456. 10.1038\/nature09291.","journal-title":"Nature"},{"issue":"7121","key":"651_CR21","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/nature05482","volume":"444","author":"SE Kahn","year":"2006","unstructured":"Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006, 444 (7121): 840-846. 10.1038\/nature05482.","journal-title":"Nature"},{"issue":"3","key":"651_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrm2327","volume":"9","author":"DM Muoio","year":"2008","unstructured":"Muoio DM, Newgard CB: Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nature reviews Molecular cell biology. 2008, 9 (3): 193-205. 10.1038\/nrm2327.","journal-title":"Nature reviews Molecular cell biology"},{"issue":"6","key":"651_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20110386","volume":"122","author":"B Viollet","year":"2012","unstructured":"Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F: Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012, 122 (6): 253-270. 10.1042\/CS20110386.","journal-title":"Clin Sci (Lond)"},{"issue":"Suppl 1","key":"651_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1472-6947-12-S1-S1","volume":"12","author":"S Lee","year":"2012","unstructured":"Lee S, Choi J, Park K, Song M, Lee D: Discovering context-specific relationships from biological literature by using multi-level context terms. BMC Medical Informatics and Decision Making. 2012, 12 (Suppl 1): S1-10.1186\/1472-6947-12-S1-S1.","journal-title":"BMC Medical Informatics and Decision Making"},{"key":"651_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1109\/WSC.2010.5679125","volume-title":"Simulation Conference (WSC), Proceedings of the 2010 Winter: 5-8 Dec. 2010 2010","author":"AT Bittig","year":"2010","unstructured":"Bittig AT, Uhrmacher AM: Spatial modeling in cell biology at multiple levels. Simulation Conference (WSC), Proceedings of the 2010 Winter: 5-8 Dec. 2010 2010. 2010, 608-619."},{"issue":"6","key":"651_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2337\/diacare.24.6.989","volume":"24","author":"JL Chiasson","year":"2001","unstructured":"Chiasson JL, Naditch L: The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes care. 2001, 24 (6): 989-994. 10.2337\/diacare.24.6.989.","journal-title":"Diabetes care"},{"issue":"6","key":"651_CR27","first-page":"1167","volume":"4","author":"MK Israel","year":"2008","unstructured":"Israel MK, Istvan E, Baron MA: Safety and efficacy of nateglinide\/metformin combination therapy in the treatment of type 2 diabetes. Vascular health and risk management. 2008, 4 (6): 1167-1178.","journal-title":"Vascular health and risk management"},{"issue":"4","key":"651_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1089\/dia.2006.0023","volume":"9","author":"M Comaschi","year":"2007","unstructured":"Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S: Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes technology & therapeutics. 2007, 9 (4): 387-398. 10.1089\/dia.2006.0023.","journal-title":"Diabetes technology & therapeutics"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6947-13-S1-S4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:57:56Z","timestamp":1630537076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/1472-6947-13-S1-S4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":28,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1186\/1472-6947-13-s1-s4","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"5 April 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"S4"}}